深圳市海王生物工程股份有限公司 关于暂不召开股东大会的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：000078 证券简称：海王生物 公告编号：2025-044 深圳市海王生物工程股份有限公司 董 事 局 二〇二五年八月十四日 深圳市海王生物工程股份有限公司（以下简称"公司"）于 2025 年 8 月 14 日 召开了第九届董事局第二十五次会议、第九届监事会第二十一次会议，会议审议 通过了《关于转让控股子公司股权被动形成对外财务资助的议案》《关于担保延 续构成对外担保的议案》。具体内容详见公司于本公告披露日在《中国证券报》 《证券时报》《证券日报》《上海证券报》及巨潮资讯网 （http://www.cninfo.co m.cn/new/index）上刊登的相关公告。 本次提供财务资助及对外担保事项尚需提交公司股东大会审议，基于公司的 工作安排需要，公司董事局决定暂不召开股东大会。公司董事局将根据工作安排 另行发布召开股东大会的通知，提请股东大会审议《关于转让控股子公司股权被 动形成对外财务资助的议案》《关于担保延续构成对外担保的议案》。 特此 ...

证券代码：000078 证券简称：海王生物 公告编号：2025-041 深圳市海王生物工程股份有限公司 （二）审议通过了《关于担保延续构成对外担保的议案》 第九届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、监事会会议召开情况 深圳市海王生物工程股份有限公司（以下简称"公司"）第九届监事会第二 十一次会议通知于 2025 年 8 月 11 日发出，并于 2025 年 8 月 14 日以通讯会议的 形式召开。会议应参与表决监事 3 人，实际参与表决监事 3 人。会议的召开和表 决程序符合《公司法》和《公司章程》的规定。 二、监事会会议审议情况 经与会监事审议，会议通过了以下议案： （一）审议通过了《关于转让控股子公司股权被动形成对外财务资助的议案》 具体内容详见公司于本公告日在《证券时报》《中国证券报》《上海证券 报》《证券日报》及巨潮资讯网上刊登的《关于转让控股子公司股权被动形成对 外财务资助的公告》。 本议案尚需提交公司股东大会审议。 表决结果：3 票同意，0 票反对，0 票弃权。 具体内容详见公司于本公告日在《证券时报》 ...

一、关于担保延续构成对外担保的意见 监事会认为，公司本次对广西海王银河医药有限公司提供担保为担保延续构成的 对外担保，被担保方提供了一定的反担保保障措施。本事项不会损害公司及全体股东 的利益，监事会同意本事项。 深圳市海王生物工程股份有限公司监事会 关于第九届监事会第二十一次会议相关事项的意见 深圳市海王生物工程股份有限公司（以下简称"公司"）于 2025 年 8 月 14 日召开 了第九届监事会第二十一次会议，监事会对相关事项发表审核意见如下： 监 事 会 二〇二五年八月十四日 深圳市海王生物工程股份有限公司 ...

证券代码：000078 证券简称：海王生物 公告编号：2025-040 深圳市海王生物工程股份有限公司 第九届董事局第二十五次会议决议公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事局会议召开情况 （二）审议通过了《关于担保延续构成对外担保的议案》 具体内容详见公司于本公告日在《证券时报》《中国证券报》《上海证券 报》《证券日报》及巨潮资讯网上刊登的《关于担保延续构成对外担保的公 告》。 本议案尚需提交公司股东大会审议。 表决结果：9 票同意，0 票反对，0 票弃权。 深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）第九届董 事局第二十五次会议的通知于2025年8月11日发出，并于2025年8月14日以通讯会 议的形式召开会议。会议应参与表决董事9人，实际参与表决董事9人。会议的召 开和表决程序符合《公司法》和《公司章程》的规定。 二、董事局会议审议情况 经与会董事审议，会议通过了以下议案： （一）审议通过了《关于转让控股子公司股权被动形成对外财务资助的议案》 具体内容详见公司于本公告日在《证券时报》《中国证券报》《上海证券 报》《 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301408 | 华人健康 | 15.11 | -1.76% | 17.96万 | 2.71亿 | | 300937 | 药易购 | 30.05 | -1.60% | 4.53万 | 1.36亿 | | 301015 | 百洋医药 | 25.98 | -1.55% | 29.18万 | 7.77亿 | | 600272 | 开开实业 | 13.87 | -1.42% | 6.94万 | 9642.32万 | | 301126 | 达嘉维康 | 13.25 | -1.41% | 14.39万 | 1.91亿 | | 603122 | 合富中国 | 7.23 | -1.36% | 6.01万 | 4356.44万 | | 002589 | 瑞康医药 | 3.05 | -1.29% | 43.86万 | 1.34亿 | | 301017 | 款玉平民 | 13.20 | -0.98% | 4.94万 | 6532.05万 | | 605266 | 健之佳 ...

金融界消息 截至2025年8月1日收盘，海王生物（000078）报收于2.8元，上涨1.82%，换手率3.26%，成 交量85.61万手，成交金额2.42亿元。 通过天眼查大数据分析，深圳市海王生物工程股份有限公司共对外投资了20家企业，知识产权方面有商 标信息1条，此外企业还拥有行政许可14个。 资金流向方面，今日主力资金净流入1395.72万元，占比成交额5.77%。其中，超大单净流入460.06万 元、占成交额1.9%，大单净流入935.66万元、占成交额3.87%，中单净流出流入75.22万元、占成交额 0.31%，小单净流出1470.94万元、占成交额6.08%。 海王生物最新一期业绩显示，截至2025一季报，公司营业总收入73.76亿元、同比减少8.81%，归属净利 润2371.58万元，同比减少44.38%，扣非净利润7474.36万元，同比减少257.78%，流动比率1.022、速动 比率0.889、资产负债率89.76%。 天眼查商业履历信息显示，深圳市海王生物工程股份有限公司，成立于1992年，位于深圳市，是一家以 从事医药制造业为主的企业。企业注册资本263112.3257万人民币，实缴 ...

Group 1 - Shengde Xintai won a bid for a thermal power steel pipe project worth approximately 217 million yuan, accounting for 8.15% of its audited revenue for 2024 [1] - High-speed Electric's subsidiary won a project for the Shanghai-Nanjing-Hefei high-speed railway, with a bid amount of 71.76 million yuan [1] - Cangge Mining's subsidiary received a construction permit for a lithium-boron mining project, with a construction area of 106,900 square meters [2] Group 2 - China Electric Power Construction signed a mining transportation project contract in Guinea worth approximately 5.063 billion yuan, with a total duration of about 72 months [3] - Guobang Pharmaceutical's subsidiary completed the registration of an equity investment fund focusing on strategic emerging industries [4] - Deshi Co. obtained two invention patents related to oil and gas field development [5][26] Group 3 - Xue Tian Salt Industry expects a significant decrease in net profit for the first half of 2025, projecting a decline of 76.34% to 80.29% [6] - Rundu Co. received a drug registration certificate for moxifloxacin hydrochloride tablets, used for treating various bacterial infections [7] - China Nuclear Power reported a 15.65% increase in power generation in the first half of the year, with nuclear power generation up by 12.01% [8] Group 4 - Suqian Liansheng obtained two invention patents related to wastewater treatment methods [9] - Boshi Co. signed a 109 million yuan operation and maintenance service contract for solid product packaging [11] - *ST Sailong's subsidiary received a drug registration certificate for torasemide injection, used for various medical conditions [13] Group 5 - North Bay Port reported a 10.95% increase in cargo throughput for the first half of 2025, with container throughput also showing growth [14] - Kaiwei Te expects a revenue increase of 56.17% to 90.87% for the first half of 2025 [15] - Wankai New Materials plans to reduce production and conduct maintenance on 60,000 tons of PET capacity, affecting overall performance [16] Group 6 - Haiwang Bio's HW130 injection successfully completed Phase I clinical trials, showing good safety and tolerability [19] - Zhenai Meijia received a total of 22.8 million yuan in compensation for land acquisition, which will significantly impact its 2025 performance [20] - Changyuan Electric reported a 23.58% decrease in power generation in June, with a notable decline in thermal power generation [21] Group 7 - Shouxiangu's subsidiary completed the registration of two health food products [22] - Kailun Co. announced the resignation of its deputy general manager and board secretary [23] - Xibu Muye reported a 2.15% year-on-year increase in fresh milk production in June [24] Group 8 - Deshi Co. obtained two invention patents related to oil and gas field development [26] - Jingwei Huikai plans to acquire a 12.44% stake in Nuo Si Micro for 149 million yuan [27] - Electric Alloy completed the registration of its subsidiary in Mexico [29] Group 9 - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of 2025 [30] - Guizhou Moutai repurchased approximately 3.38 million shares, accounting for 0.2692% of its total share capital [31][32] - Warner Pharmaceutical received approval for the listing application of a raw material drug for treating respiratory diseases [34] Group 10 - Yuan Dong Bio's independent director is under investigation for serious violations [35] - Dash Intelligent signed a contract for a smart project worth 11.88 million yuan [36] - Dayou Energy plans to transfer 586,500 tons of coal production capacity replacement indicators [37] Group 11 - Foton Motor reported a 150.96% increase in new energy vehicle sales in the first half of 2025 [39] - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [40] - Zongshen Power expects a net profit increase of 70% to 100% for the first half of 2025 [42] Group 12 - Yingboer plans to sell its wholly-owned subsidiary for 239 million yuan [44] - Changan Automobile reported a 1.59% increase in total vehicle sales in the first half of 2025 [46] - Fulian Precision signed a cooperation framework agreement with Sichuan Development Longmang [48] Group 13 - Nengte Technology plans to repurchase shares worth 300 million to 500 million yuan [50] - Longsoft Technology's controlling shareholder donated 3.43% of the company's shares [51] - Data Port's shareholders plan to reduce their holdings by up to 2% [52]

Core Viewpoint - The strong stock performance of Haiwang Biological on July 2 reflects market confidence in its strategic transformation and the potential of the "ocean economy + innovative drugs" dual-track approach, especially in light of favorable national policies [1][5]. Policy Support and Market Opportunities - The Chinese government is emphasizing high-quality development of the ocean economy, with a focus on deep-sea technology as a core driver for high value-added industry transformation [2]. - Haiwang Biological is positioned to benefit from policies supporting innovative drug development, particularly through its established research center in Shenzhen, which focuses on marine drug development for critical diseases [2]. - Recent measures from the National Healthcare Security Administration and the National Health Commission aim to support innovative drug development across the entire chain, which will directly benefit Haiwang Biological's product pipeline [2]. Strategic Focus and Financial Optimization - Haiwang Biological is concentrating on high-margin, high-tech areas, aligning with national policies that encourage differentiated innovation, which is expected to enhance its profitability and competitive edge [3]. - The company is optimizing its capital structure by disposing of non-core assets and reducing debt, which will provide resources for future strategic initiatives in marine biomedicine and internationalization [4]. - The internationalization strategy includes partnerships with global research institutions and compliance with international standards, aiming to capture opportunities in high-growth pharmaceutical markets [4]. Market Confidence and Valuation - Haiwang Biological's stock has been undervalued compared to its innovative drug potential, and the recent policy support creates a rare resonance between the ocean economy and innovative drugs, driving strong valuation recovery momentum [4]. - The market's positive response to Haiwang Biological's strategic direction indicates a strong belief in its growth potential amid favorable policy conditions [5].

Group 1 - The core viewpoint is that Haiwang Bio's stock surged by 10.12% to 2.72 yuan per share, reaching a three-month high, reflecting strong market expectations for its strategic transformation amid ongoing policy support in the pharmaceutical industry [1] - The company experienced a net capital inflow of over 350 million yuan and a turnover rate of 5.04%, indicating active market participation [1] - Haiwang Bio is focusing on innovative drug research and development to establish a second growth curve, leveraging its status as a long-established enterprise with a marine drug research center in Shenzhen [1] Group 2 - The surge in Haiwang Bio's stock is closely linked to favorable policies in the pharmaceutical sector, particularly the recent measures issued by the National Healthcare Security Administration and the National Health Commission to support high-quality development of innovative drugs [2] - The company plans to expand its medical device agency business by 30% and extend into upstream manufacturing, creating a closed-loop ecosystem of "research - production - sales" [2] - Haiwang Bio's medical device segment generated revenue of 9.588 billion yuan, which supports its strategy for domestic substitution [2] Group 3 - Despite facing revenue fluctuations due to centralized procurement policies over the past three years, Haiwang Bio reported a net profit of 2.37158 million yuan in Q1 2025, indicating signs of marginal improvement [3] - The company's debt-to-asset ratio has decreased to 89.76%, suggesting improved financing channels that provide financial support for its operations [3] - With a current price-to-sales ratio (TTM) of only 0.2 and a price-to-book ratio of 3.94, Haiwang Bio's valuation is significantly lower than the industry average, positioning it for potential transformation from a "pharmaceutical distributor" to a "comprehensive medical service enterprise" [3]

剂型：注射液 证券代码：000078 证券简称：海王生物 公告编号：2025-039 深圳市海王生物工程股份有限公司 关于 HW130 注射液完成 I 期临床试验的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、概述 深圳市海王生物工程股份有限公司(以下简称"公司"或"本公司")全资子 公司深圳海王医药科技研究院有限公司(以下简称"海王医药研究院")研发的 HW130注射液已于近日完成I期临床试验，并取得I期临床研究报告。现将相关情 况公告如下： 二、基本情况 药品名称：HW130 注册分类：化学药品1类 适应症：经标准治疗失败的晚期恶性实体瘤 临床试验分期：I期临床试验 研究方法：单次、多次给药安全性、耐受性及药代动力学研究 申办方：深圳海王医药科技研究院有限公司 三、研发情况 HW130注射液是海王医药研究院自主研发、具有自主知识产权的新型抗肿 瘤药物，分别获得国家药品监督管理局、美国FDA临床试验许可。具有肿瘤血 管阻断作用以及降低肿瘤化疗治疗严重不良反应和化疗增敏作用，提升肿瘤综 合治疗的临床效益；对正常器官组织的损伤轻微，具有高度的靶向性。 ...